2月26日,国家药监局药品审评中心(CDE)官网披露,诺和诺德的1类新药amycretin注射液获批临床试验,拟用于降低超重或肥胖成人患者的体重。该药为长效GLP-1和胰淀素受体激动剂。今年以来,包括华东医药等在内的多家企业研发的双靶点GLP-1激动剂在减重适应症上迎来研发新进展,受到资本市场关注。 新剂型首次国内获批 诺和诺德此次获批减重适应症临床的GLP-1和胰淀素受体激动剂...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.